EXELIXIS, INC.EXELEarnings & Financial Report
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
EXEL Q4 2026 Key Financial Metrics
売上高
$598.7M
粗利益
$572.2M
営業利益
$235.2M
純利益
$244.5M
粗利益率
95.6%
営業利益率
39.3%
純利益率
40.8%
前年比成長
5.6%
EPS
$0.89
資金フロー
EXELIXIS, INC. Q4 2026 Financial Summary
EXELIXIS, INC. reported revenue of $598.7M (up 5.6% YoY) for Q4 2026, with a net profit of $244.5M (up 74.8% YoY) (40.8% margin). Cost of goods sold was $26.5M, operating expenses totaled $337.0M.
Key Financial Metrics
| Total Revenue | $598.7M |
|---|---|
| Net Profit | $244.5M |
| Gross Margin | 95.6% |
| Operating Margin | 39.3% |
| Report Period | Q4 2026 |
EXELIXIS, INC. Annual Revenue by Year
EXELIXIS, INC. annual revenue history includes year-by-year totals (for example, 2026 revenue was $2.3B). Click any linked year to see what changed vs the prior 10-K.
EXELIXIS, INC. Quarterly Revenue & Net Profit History
EXELIXIS, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2026 | $598.7M | +5.6% | $244.5M | 40.8% |
| Q3 2026 | $597.8M | +10.8% | $193.6M | 32.4% |
| Q2 2026 | $568.3M | -10.8% | $184.8M | 32.5% |
| Q1 2026 | $555.4M | +30.6% | $159.6M | 28.7% |
| Q4 2025 | $566.8M | +18.2% | $139.9M | 24.7% |
| Q3 2025 | $539.5M | +14.3% | $118.0M | 21.9% |
| Q2 2025 | $637.2M | +35.6% | $226.1M | 35.5% |
| Q1 2025 | $425.2M | +4.0% | $37.3M | 8.8% |
損益計算書
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $425.2M | $637.2M | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M |
| 前年比成長 | 4.0% | 35.6% | 14.3% | 18.2% | 30.6% | -10.8% | 10.8% | 5.6% |
貸借対照表
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $2.80B | $2.77B | $2.96B | $2.95B | $2.84B | $2.68B | $2.82B | $2.84B |
| 総負債 | $675.7M | $653.4M | $684.9M | $703.5M | $706.2M | $644.5M | $662.8M | $683.1M |
| 株主資本 | $2.13B | $2.12B | $2.28B | $2.24B | $2.13B | $2.03B | $2.16B | $2.16B |
キャッシュフロー
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $68.8M | $119.5M | $271.3M | $240.3M | $211.4M | $49.0M | $290.3M | $333.5M |